Hypothyroidism News and Research RSS Feed - Hypothyroidism News and Research

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.
Initial congenital hypothyroidism severity predicts later cortical abnormalities

Initial congenital hypothyroidism severity predicts later cortical abnormalities

Research suggests that the persistent cognitive defects seen in children with congenital hypothyroidism, despite optimal care, are associated with altered cortical thickness. [More]
Absence of thyroid hormone during development can cause congenital deafness

Absence of thyroid hormone during development can cause congenital deafness

Fatigue, weight gain, chills, hair loss, anxiety, excessive perspiration - these symptoms are a few of the signs that the thyroid gland, which regulates the body's heart rate and plays a crucial role in its metabolism, has gone haywire. [More]
High levels of pervasive chemical in women may lead to adverse effects in offspring

High levels of pervasive chemical in women may lead to adverse effects in offspring

In some women abnormally high levels of a common and pervasive chemical may lead to adverse effects in their offspring. [More]
Thyroxine may overcome mutated thyroid hormone receptor effects

Thyroxine may overcome mutated thyroid hormone receptor effects

Patients with a mutation in the thyroid hormone receptor α gene that affects both the thyroid hormone receptor α1 and α2 protein variants have similar characteristics to patients with mutations affecting only the α1 variant, report researchers. [More]
Hormonal imbalance is not the sole cause of childhood obesity, say experts

Hormonal imbalance is not the sole cause of childhood obesity, say experts

The number of children who are obese remains alarmingly high in the U.S. and, unfortunately, diseases associated with obesity are on the rise. [More]
People with significant hypothyroidism can experience impaired driving

People with significant hypothyroidism can experience impaired driving

People with significant hypothyroidism can experience impaired driving similar to those who are driving when intoxicated by alcohol, a new study finds. [More]
Grain legume crops overlooked as potentially valuable sources of micronutrients

Grain legume crops overlooked as potentially valuable sources of micronutrients

Popular diets across the world typically focus on the right balance of essential components like protein, fat, and carbohydrates. These items are called macronutrients, and we consume them in relatively large quantities. [More]
Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO

Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFRα-β). [More]
AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL). [More]
Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3. [More]
Free educational event for patients with Graves' disease and thyroid eye disease

Free educational event for patients with Graves' disease and thyroid eye disease

The Massachusetts Eye and Ear and the Graves' Disease & Thyroid Foundation will host a free educational event for patients living with Graves' disease and thyroid eye disease on Saturday, May 10 from 8:30 a.m. to noon at Mass. Eye and Ear's Meltzer Auditorium, 3rd floor, 243 Charles Street, Boston, Mass., 02114. [More]
Researcher explores public perceptions related to newborn screening programs

Researcher explores public perceptions related to newborn screening programs

While 94 per cent of Canadians surveyed said they would participate in public health programs that screen newborns for a specific number of genetic conditions, only 80 per cent said they would be willing to participate in screening that would sequence their newborns' genomes. [More]
Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized. [More]
Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012. [More]
TV series House helps doctors diagnose Cobalt intoxication of patient with hip replacement

TV series House helps doctors diagnose Cobalt intoxication of patient with hip replacement

In today’s edition of The Lancet [Friday 7 February], doctors report the case of a patient with severe heart failure, who in May 2012 was referred to the Marburg University clinic in Germany. [More]
Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets. [More]
New American Cancer Society report calls diagnosis of childhood cancer

New American Cancer Society report calls diagnosis of childhood cancer

A new report from the American Cancer Society outlines progress made and -more importantly-challenges that remain in fighting childhood cancer. The report estimates the number of new cancer cases and deaths for children and adolescents in the United States, summarizes the most recent and comprehensive data on cancer incidence, mortality, and survival, and outlines what is known and where answers are still needed for childhood cancers. [More]
AACE releases first 2013 list of most frequently searched endocrine medical conditions

AACE releases first 2013 list of most frequently searched endocrine medical conditions

The American Association of Clinical Endocrinologists (AACE) today released its first annual list of the most frequently searched endocrine medical conditions for 2013, as measured by visits to the organization's patient education website, www.empoweryourhealth.org. [More]
Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La. [More]
Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). [More]